Physician profile
Mark D Lauron
NPI 1932179595
$4,198.66
in general payments reported to CMS, 2019-2025
19 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $557 · 2021: $481 · 2022: $640 · 2023: $790 · 2024: $641 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,377.52 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,254.40 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $453.58 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Pfizer INC. | $168.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $142.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.95 | 2019-2023 | Jardiance |
| Grifols USA, LLC | $125.00 | 2023 | Hyperrab |
| Teva Pharmaceuticals USA, INC. | $98.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $89.84 | 2019-2022 | |
| Lilly USA, LLC | $86.03 | 2022-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $53.67 | 2022-2023 | Eliquis |
| Amarin Pharma, INC. | $43.96 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.30 | 2024 | Trelegy Ellipta |
| Amgen INC. | $22.78 | 2024 | Repatha, Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.56 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.79 | 2023 | Horizant |
| Biohaven Pharmaceuticals, INC. | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lauron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.